PMID- 34235880
OWN - NLM
STAT- MEDLINE
DCOM- 20210913
LR  - 20210913
IS  - 2151-4658 (Electronic)
IS  - 2151-464X (Linking)
VI  - 73
IP  - 8
DP  - 2021 Aug
TI  - 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the 
      Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
PG  - 1088-1105
LID - 10.1002/acr.24634 [doi]
AB  - OBJECTIVE: To provide evidence-based recommendations and expert guidance for the 
      management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), 
      including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), 
      and eosinophilic granulomatosis with polyangiitis (EGPA). METHODS: Clinical 
      questions regarding the treatment and management of AAV were developed in the 
      population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 
      34 for EGPA). Systematic literature reviews were conducted for each PICO 
      question. The Grading of Recommendations Assessment, Development and Evaluation 
      methodology was used to assess the quality of evidence and formulate 
      recommendations. Each recommendation required >/=70% consensus among the Voting 
      Panel. RESULTS: We present 26 recommendations and 5 ungraded position statements 
      for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. 
      This guideline provides recommendations for remission induction and maintenance 
      therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These 
      recommendations include the use of rituximab for remission induction and 
      maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. 
      All recommendations are conditional due in part to the lack of multiple 
      randomized controlled trials and/or low-quality evidence supporting the 
      recommendations. CONCLUSION: This guideline presents the first recommendations 
      endorsed by the American College of Rheumatology and the Vasculitis Foundation 
      for the management of AAV and provides guidance to health care professionals on 
      how to treat these diseases.
CI  - (c) 2021, American College of Rheumatology.
FAU - Chung, Sharon A
AU  - Chung SA
AD  - University of California, San Francisco.
FAU - Langford, Carol A
AU  - Langford CA
AD  - Cleveland Clinic, Cleveland, Ohio.
FAU - Maz, Mehrdad
AU  - Maz M
AUID- ORCID: 0000-0002-3594-0508
AD  - University of Kansas Medical Center, Kansas City.
FAU - Abril, Andy
AU  - Abril A
AD  - Mayo Clinic, Jacksonville, Florida.
FAU - Gorelik, Mark
AU  - Gorelik M
AD  - Columbia University, New York, New York.
FAU - Guyatt, Gordon
AU  - Guyatt G
AD  - McMaster University, Hamilton, Ontario, Canada.
FAU - Archer, Amy M
AU  - Archer AM
AD  - Northwestern University, Chicago, Illinois.
FAU - Conn, Doyt L
AU  - Conn DL
AUID- ORCID: 0000-0003-3303-3944
AD  - Emory University, Atlanta, Georgia.
FAU - Full, Kathy A
AU  - Full KA
AD  - Springfield, Illinois.
FAU - Grayson, Peter C
AU  - Grayson PC
AUID- ORCID: 0000-0002-8269-9438
AD  - National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, 
      Bethesda, Maryland.
FAU - Ibarra, Maria F
AU  - Ibarra MF
AD  - Children's Mercy Hospital, Kansas City, Missouri.
FAU - Imundo, Lisa F
AU  - Imundo LF
AD  - Columbia University, New York, New York.
FAU - Kim, Susan
AU  - Kim S
AD  - University of California, San Francisco.
FAU - Merkel, Peter A
AU  - Merkel PA
AUID- ORCID: 0000-0001-9284-7345
AD  - University of Pennsylvania, Philadelphia.
FAU - Rhee, Rennie L
AU  - Rhee RL
AUID- ORCID: 0000-0002-4907-0304
AD  - University of Pennsylvania, Philadelphia.
FAU - Seo, Philip
AU  - Seo P
AD  - Johns Hopkins University, Baltimore, Maryland.
FAU - Stone, John H
AU  - Stone JH
AUID- ORCID: 0000-0001-6588-9435
AD  - Massachusetts General Hospital, Boston.
FAU - Sule, Sangeeta
AU  - Sule S
AUID- ORCID: 0000-0002-5876-376X
AD  - Children's National Hospital, Washington, DC.
FAU - Sundel, Robert P
AU  - Sundel RP
AD  - Boston Children's Hospital, Boston, Massachusetts.
FAU - Vitobaldi, Omar I
AU  - Vitobaldi OI
AD  - Chicago, Illinois.
FAU - Warner, Ann
AU  - Warner A
AD  - Saint Luke's Health System, Kansas City, Missouri.
FAU - Byram, Kevin
AU  - Byram K
AD  - Vanderbilt University, Nashville, Tennessee.
FAU - Dua, Anisha B
AU  - Dua AB
AD  - Northwestern University, Chicago, Illinois.
FAU - Husainat, Nedaa
AU  - Husainat N
AUID- ORCID: 0000-0002-9638-2992
AD  - SSM Health-St. Mary's Hospital, St. Louis, Missouri.
FAU - James, Karen E
AU  - James KE
AD  - University of Utah, Salt Lake City.
FAU - Kalot, Mohamad A
AU  - Kalot MA
AUID- ORCID: 0000-0002-6581-4561
AD  - State University of New York at Buffalo.
FAU - Lin, Yih Chang
AU  - Lin YC
AD  - University of South Florida, Tampa.
FAU - Springer, Jason M
AU  - Springer JM
AUID- ORCID: 0000-0002-3903-6049
AD  - University of Kansas Medical Center, Kansas City.
FAU - Turgunbaev, Marat
AU  - Turgunbaev M
AD  - American College of Rheumatology, Atlanta, Georgia.
FAU - Villa-Forte, Alexandra
AU  - Villa-Forte A
AD  - Cleveland Clinic, Cleveland, Ohio.
FAU - Turner, Amy S
AU  - Turner AS
AUID- ORCID: 0000-0001-7695-2022
AD  - American College of Rheumatology, Atlanta, Georgia.
FAU - Mustafa, Reem A
AU  - Mustafa RA
AUID- ORCID: 0000-0002-2091-0875
AD  - University of Kansas Medical Center, Kansas City, and McMaster University, 
      Hamilton, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20210708
PL  - United States
TA  - Arthritis Care Res (Hoboken)
JT  - Arthritis care & research
JID - 101518086
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - 0 (Biomarkers)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis/*drug 
      therapy/immunology
MH  - Antibodies, Antineutrophil Cytoplasmic/*blood
MH  - Biomarkers/blood
MH  - Clinical Decision-Making
MH  - Consensus
MH  - Decision Support Techniques
MH  - Evidence-Based Medicine/standards
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects/*therapeutic use
MH  - Rheumatology/*standards
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2021/07/09 06:00
MHDA- 2021/09/14 06:00
CRDT- 2021/07/08 07:13
PHST- 2020/09/25 00:00 [received]
PHST- 2021/04/13 00:00 [accepted]
PHST- 2021/07/09 06:00 [pubmed]
PHST- 2021/09/14 06:00 [medline]
PHST- 2021/07/08 07:13 [entrez]
AID - 10.1002/acr.24634 [doi]
PST - ppublish
SO  - Arthritis Care Res (Hoboken). 2021 Aug;73(8):1088-1105. doi: 10.1002/acr.24634. 
      Epub 2021 Jul 8.